Weiss Asset Management LP Takes $6.84 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Weiss Asset Management LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 28,864 shares of the medical research company's stock, valued at approximately $6,840,000.

Other large investors have also made changes to their positions in the company. FMR LLC raised its position in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA in the 3rd quarter valued at about $147,683,000. 1832 Asset Management L.P. boosted its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock worth $96,487,000 after buying an additional 376,595 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of IQVIA during the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc lifted its position in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after acquiring an additional 264,555 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on IQV shares. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Leerink Partners reissued an "outperform" rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Trading Up 1.4 %

NYSE:IQV traded up $2.70 on Friday, reaching $202.63. 1,388,027 shares of the company's stock were exchanged, compared to its average volume of 1,179,056. The business has a fifty day moving average of $215.82 and a 200-day moving average of $225.33. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a market capitalization of $36.78 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 2.06 and a beta of 1.49.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.